These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

574 related items for PubMed ID: 24664227

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Ubiquinol (reduced Coenzyme Q10) in patients with severe sepsis or septic shock: a randomized, double-blind, placebo-controlled, pilot trial.
    Donnino MW, Mortensen SJ, Andersen LW, Chase M, Berg KM, Balkema J, Radhakrishnan J, Gazmuri RJ, Liu X, Cocchi MN.
    Crit Care; 2015 Jul 01; 19(1):275. PubMed ID: 26130237
    [Abstract] [Full Text] [Related]

  • 23. Determinants of the timing of symptomatic treatment in early Parkinson disease: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) Experience.
    Parashos SA, Swearingen CJ, Biglan KM, Bodis-Wollner I, Liang GS, Ross GW, Tilley BC, Shulman LM, NET-PD Investigators.
    Arch Neurol; 2009 Sep 01; 66(9):1099-104. PubMed ID: 19597081
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study. Parkinson Study Group.
    JAMA; 1997 Jul 09; 278(2):125-30. PubMed ID: 9214527
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. A randomized, double-blind, placebo-controlled study of oral coenzyme Q10 to relieve self-reported treatment-related fatigue in newly diagnosed patients with breast cancer.
    Lesser GJ, Case D, Stark N, Williford S, Giguere J, Garino LA, Naughton MJ, Vitolins MZ, Lively MO, Shaw EG, Wake Forest University Community Clinical Oncology Program Research Base.
    J Support Oncol; 2013 Mar 09; 11(1):31-42. PubMed ID: 22682875
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease.
    NINDS NET-PD InvestigatorsUniversity of Rochester Medical Center, 1351 Mt. Hope Ave., Ste. 223, Rochester, NY 14620, USA..
    Neurology; 2007 Jan 02; 68(1):20-8. PubMed ID: 17200487
    [Abstract] [Full Text] [Related]

  • 34. Effects of Coenzyme Q10 Supplementation on Exercise Performance and Markers of Oxidative Stress in Hemodialysis Patients: A Double-Blind Placebo-Controlled Crossover Trial.
    Gokbel H, Turk S, Okudan N, Atalay H, Belviranli M, Gaipov A, Solak Y.
    Am J Ther; 2016 Jan 02; 23(6):e1736-e1743. PubMed ID: 26844861
    [Abstract] [Full Text] [Related]

  • 35. Coenzyme Q10 as a potential add-on treatment for patients suffering from painful diabetic neuropathy: results of a placebo-controlled randomized trial.
    Amini P, Sajedi F, Mirjalili M, Mohammadi Y, Mehrpooya M.
    Eur J Clin Pharmacol; 2022 Dec 02; 78(12):1899-1910. PubMed ID: 36273066
    [Abstract] [Full Text] [Related]

  • 36. Altered redox state of platelet coenzyme Q10 in Parkinson's disease.
    Götz ME, Gerstner A, Harth R, Dirr A, Janetzky B, Kuhn W, Riederer P, Gerlach M.
    J Neural Transm (Vienna); 2000 Dec 02; 107(1):41-8. PubMed ID: 10809402
    [Abstract] [Full Text] [Related]

  • 37. A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data.
    Pagano G, Boess FG, Taylor KI, Ricci B, Mollenhauer B, Poewe W, Boulay A, Anzures-Cabrera J, Vogt A, Marchesi M, Post A, Nikolcheva T, Kinney GG, Zago WM, Ness DK, Svoboda H, Britschgi M, Ostrowitzki S, Simuni T, Marek K, Koller M, Sevigny J, Doody R, Fontoura P, Umbricht D, Bonni A, PASADENA Investigators, Prasinezumab Study Group.
    Front Neurol; 2021 Dec 02; 12():705407. PubMed ID: 34659081
    [Abstract] [Full Text] [Related]

  • 38. Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
    Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury K, Hibbert S, Budnik N, Zampedri L, Dickson J, Li Y, Aviles-Olmos I, Warner TT, Limousin P, Lees AJ, Greig NH, Tebbs S, Foltynie T.
    Lancet; 2017 Oct 07; 390(10103):1664-1675. PubMed ID: 28781108
    [Abstract] [Full Text] [Related]

  • 39. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease.
    NINDS NET-PD Investigators.
    Neurology; 2006 Mar 14; 66(5):664-71. PubMed ID: 16481597
    [Abstract] [Full Text] [Related]

  • 40. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
    Parkinson Study Group.
    JAMA; 2000 Oct 18; 284(15):1931-8. PubMed ID: 11035889
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 29.